LAVA Therapeutics N.V.

Equities

LVTX

NL0015000AG6

Biotechnology & Medical Research

Delayed Nasdaq Other stock markets 03:57:20 2024-05-10 pm EDT			5-day change	1st Jan Change
3.09 ^USD	-0.64%		+1.98%	+95.57%

Mar. 20	LAVA Therapeutics N.V. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 20	LAVA Therapeutics N.V. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	CI

LAVA Therapeutics N.V. Reports Earnings Results for the First Quarter Ended March 31, 2022

May 17, 2022 at 04:09 pm EDT

LAVA Therapeutics N.V. reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported revenue was USD 1 million compared to USD 1 million a year ago. Net loss was USD 10.56 million compared to USD 19.74 million a year ago. Basic loss per share from continuing operations was USD 0.41 compared to USD 12.14 a year ago.

Latest news about LAVA Therapeutics N.V.

LAVA Therapeutics N.V. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 20	CI
LAVA Therapeutics N.V. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 20	CI
LAVA Therapeutics N.V. Announces Clinical Development Milestone Achieved by Pfizer for PF-08046052	Mar. 05	CI
Sector Update: Health Care Stocks Softer Late Afternoon	Jan. 25	MT
Sector Update: Health Care Stocks Slipping Thursday Afternoon	Jan. 25	MT
Sector Update: Health Care	Jan. 25	MT
Lava Therapeutics to Study Gammabody Combined With Merck's Keytruda to Treat Metastatic Prostate Cancer	Jan. 25	MT
Upbeat US Economic Growth Data Lift Sentiment, Driving Premarket Gains for US Equity Futures	Jan. 25	MT
Lava Therapeutics Shares Rise as Drug Set for Test With Merck's Keytruda	Jan. 25	DJ
Top Premarket Gainers	Jan. 25	MT
LAVA Therapeutics Announces Collaboration with Merck & Co., Inc. to Evaluate LAVA-1207 in Combination with KEYTRUDA	Jan. 25	CI
LAVA Therapeutics N.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 16	CI
HC Wainwright Adjusts Price Target on Lava Therapeutics to $6 From $9, Maintains Buy Rating	23-08-23	MT
LAVA Therapeutics N.V. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-22	CI
Lava Therapeutics to Halt LAVA-051 Clinical Trial, Focus on Potential Prostate Cancer Treatment LAVA-1207	23-06-14	MT
LAVA Therapeutics N.V. Provides Updates on Clinical Programs and Extends the Cash Runway	23-06-14	CI
LAVA Therapeutics N.V. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-06-08	CI
Sector Update: Health Care Stocks Rising Late Friday	23-06-02	MT
Sector Update: Health Care	23-06-02	MT
Top Midday Gainers	23-06-02	MT
Top Premarket Gainers	23-06-02	MT
LAVA Therapeutics Shares Rise Premarket Following Selection by Janssen Biotech to Support Development of Cancer Treatment	23-06-02	MT
North American Morning Briefing : Stock Futures Rise as Jobs Report Swings Into Focus	23-06-02	DJ
Stocks to Watch : Lululemon, Lava Therapeutics, Tilly's, Oncorus	23-06-01	DJ
LAVA Therapeutics N.V. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-04-11	CI

Chart LAVA Therapeutics N.V.

Duration

Period

More charts

Company Profile

LAVA Therapeutics NV, formerly known as Lava Therapeutics BV, is a provider of biotechnology research and development services based in the Netherlands. The Company focuses of developing next generation Vdelta T cell engaging bispecific antibodies to fight cancer.

Sector

Biotechnology & Medical Research

Calendar

2024-05-13 - Citizens JMP Life Sciences Conference

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.886 EUR

Average target price

6.684 EUR

Spread / Average Target

+131.56%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
LAVA THERAPEUTICS N.V.	+95.57%	81.76M
MODERNA, INC.	+18.00%	47.02B
LONZA GROUP AG	+48.77%	41.86B
IQVIA HOLDINGS INC.	+1.13%	41.76B
CELLTRION, INC.	-4.27%	28.8B
ICON PUBLIC LIMITED COMPANY	+11.32%	26.05B
ALNYLAM PHARMACEUTICALS, INC.	-21.28%	19.15B
BIO-TECHNE CORPORATION	+4.76%	12.55B
MEDPACE HOLDINGS, INC.	+27.41%	12.34B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.73%	11.82B

Other Biotechnology & Medical Research